Shouhao Zhou

Dr. Shouhao Zhou

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2019 in European Heart Journal
Verified
Journal Article
Open access
PDF file
KSKathleen Sturgeon
Kathleen Sturgeon
LDLei Deng
Lei Deng
SBShirley M Bluethmann
Shirley M Bluethmann
Shouhao ZhouShouhao Zhou
Shouhao Zhou
DTDaniel M Trifiletti
Daniel M Trifiletti
NZNicholas G Zaorsky
Nicholas G Zaorsky
Aims: This observational study characterized cardiovascular disease (CVD) mortality risk for multiple cancer sites, with respect to the following: (i) continuous calendar year, (ii) age at diagnosis, and (iii) follow-up time after diagnosis. Methods and results: The Surveillance, Epidemiology, and End Results program was used to compare the US general population to 3 234 256 US cancer survivors (1973–2012). Standardized mortality ratios (SMRs) were calculated using coded cause of death from CVDs (heart disease, hypertension, cerebrovascular disease, atherosclerosis, and aortic aneurysm/dissection). Analyses were adjusted by age, race, and sex. Among 28 cancer types, 1 228 328 patients (38.0%) died from cancer and 365 689 patients (11.3%) died from CVDs. Among CVDs, 76.3% of deaths were due to heart disease. In eight cancer sites, CVD mortality risk surpassed index-cancer mortality risk in at least one calendar year. Cardiovascular disease mortality risk was highest in survivors diagnosed at <35 years of age. Further, CVD mortality risk is highest (SMR 3.93, 95% confidence interval 3.89–3.97) within the first year after cancer diagnosis, and CVD mortality risk remains elevated throughout follow-up compared to the general population. Conclusion: The majority of deaths from CVD occur in patients diagnosed with breast, prostate, or bladder cancer. We observed that from the point of cancer diagnosis forward into survivorship cancer patients (all sites) are at elevated risk of dying from CVDs compared to the general US population. In endometrial cancer, the first year after diagnosis poses a very high risk of dying from CVDs, supporting early involvement of cardiologists in such patients.

25 February 2016 in JCI Insight
Verified
Journal Article
Closed access
PDF file
KGKonrad Gabrusiewicz
Konrad Gabrusiewicz
BRBenjamin Rodriguez
Benjamin Rodriguez
JWJun Wei
Jun Wei
YHYuuri Hashimoto
Yuuri Hashimoto
LHLuke M. Healy
Luke M. Healy
Amy B. HeimbergerAmy B. Heimberger
Amy B. Heimberger
Glioblastomas are highly infiltrated by diverse immune cells, including microglia, macrophages, and myeloid-derived suppressor cells (MDSCs). Understanding the mechanisms by which glioblastoma-associated myeloid cells (GAMs) undergo metamorphosis into tumor-supportive cells, characterizing the heterogeneity of immune cell phenotypes within glioblastoma subtypes, and discovering new targets can help the design of new efficient immunotherapies. In this study, we performed a comprehensive battery of immune phenotyping, whole-genome microarray analysis, and microRNA expression profiling of GAMs with matched blood monocytes, healthy donor monocytes, normal brain microglia, nonpolarized M0 macrophages, and polarized M1, M2a, M2c macrophages. Glioblastoma patients had an elevated number of monocytes relative to healthy donors. Among CD11b+ cells, microglia and MDSCs constituted a higher percentage of GAMs than did macrophages. GAM profiling using flow cytometry studies revealed a continuum between the M1- and M2-like phenotype. Contrary to current dogma, GAMs exhibited distinct immunological functions, with the former aligned close to nonpolarized M0 macrophages.

19 November 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JWJun Wei
Jun Wei
AMAnantha Marisetty
Anantha Marisetty
BSBrett Schrand
Brett Schrand
KGKonrad Gabrusiewicz
Konrad Gabrusiewicz
YHYuuri Hashimoto
Yuuri Hashimoto
Amy B. HeimbergerAmy B. Heimberger
Amy B. Heimberger
Glioblastoma is highly enriched with macrophages, and osteopontin (OPN) expression levels correlate with glioma grade and the degree of macrophage infiltration, thus we studied whether OPN plays a crucial role in immune modulation. Quantitative PCR, immune blotting, and ELISA were used to determine OPN expression. Knockdown of OPN was achieved using complementary siRNA, shRNA and CRISPR/CAS9 techniques followed by a series of in vitro functional migration and immunological assays. OPN gene-deficient mice were used to examine the roles of non-tumor-derived OPN on survival of mice harboring intracranial gliomas. Patients with mesenchymal GBM show high OPN expression, a negative survival prognosticator. OPN is a potent chemokine for macrophages, and its blockade significantly impaired the ability of glioma cells to recruit macrophages. Integrin αVβ5 (ITGαVβ5) is highly expressed on glioblastoma-infiltrating macrophages and constitutes a major OPN receptor. OPN maintains the M2 macrophage gene signature and phenotype. Both tumor-derived OPN and host-derived OPN was critical for glioma development. OPN deficiency in either the innate immune or glioma cells demonstrated a marked reduction of M2 macrophages and elevated T cell effector activity infiltrating the glioma. Furthermore, OPN deficiency in the glioma cells sensitized them to direct CD8+ T cell cytotoxicity. OPN can be exploited as an immune modulatory target, with efficacious therapeutic results using systemically administered OPN-4-1BB bispecific aptamers, increasing median survival time by 68% (P < 0.05). OPN is an important chemokine for recruiting macrophages to glioblastoma, mediates crosstalk between tumor cells and the innate immune system, and can be exploited as a therapeutic target.

16 January 2018 in OncoImmunology
Verified
Journal Article
Open access
KGKonrad Gabrusiewicz
Konrad Gabrusiewicz
XLXu Li
Xu Li
JWJun Wei
Jun Wei
YHYuuri Hashimoto
Yuuri Hashimoto
AMAnantha L. Marisetty
Anantha L. Marisetty
Amy B. HeimbergerAmy B. Heimberger
Amy B. Heimberger
Exosomes can mediate a dynamic method of communication between malignancies, including those sequestered in the central nervous system and the immune system. We sought to determine whether exosomes from glioblastoma (GBM)-derived stem cells (GSCs) can induce immunosuppression. We report that GSC-derived exosomes (GDEs) have a predilection for monocytes, the precursor to macrophages. The GDEs traverse the monocyte cytoplasm, cause a reorganization of the actin cytoskeleton, and skew monocytes toward the immune suppresive M2 phenotype, including programmed death-ligand 1 (PD-L1) expression. Mass spectrometry analysis demonstrated that the GDEs contain a variety of components, including members of the signal transducer and activator of transcription 3 (STAT3) pathway that functionally mediate this immune suppressive switch. Western blot analysis revealed that upregulation of PD-L1 in GSC exosome-treated monocytes and GBM-patient-infiltrating CD14+ cells predominantly correlates with increased phosphorylation of STAT3, and in some cases, with phosphorylated p70S6 kinase and Erk1/2. Cumulatively, these data indicate that GDEs are secreted GBM-released factors that are potent modulators of the GBM-associated immunosuppressive microenvironment.

8 May 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LZLiang Zhang
Liang Zhang
YYYixin Yao
Yixin Yao
SZShaojun Zhang
Shaojun Zhang
YLYang Liu
Yang Liu
HGHui Guo
Hui Guo
MWMichael Wang
Michael Wang
Targeting oxidative phosphorylation overcomes ibrutinib resistance in mantle cell lymphoma.

29 August 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RGRachel B. Ger
Rachel B. Ger
Shouhao ZhouShouhao Zhou
Shouhao Zhou
PCPai-Chun Melinda Chi
Pai-Chun Melinda Chi
HLHannah J. Lee
Hannah J. Lee
RLRick Layman
Rick Layman
DMDennis Mackin
Dennis Mackin
Radiomics has shown promise in improving models for predicting patient outcomes. However, to maximize the information gain of the radiomics features, especially in larger patient cohorts, the variability in radiomics features owing to differences between scanners and scanning protocols must be accounted for. To this aim, the imaging variability of radiomics feature values was evaluated on 100 computed tomography scanners at 35 clinics by imaging a radiomics phantom using a controlled protocol and the commonly used chest and head protocols of the local clinic. We used a linear mixed-effects model to determine the degree to which the manufacturer and individual scanners contribute to the overall variability. Using a controlled protocol reduced the overall variability by 57% and 52% compared to the local chest and head protocols respectively. The controlled protocol also reduced the relative contribution of the manufacturer to the total variability. For almost all variabilities (manufacturer, scanner, and residual with different preprocesssing), the controlled protocol scans had a significantly smaller variability than the local protocol scans did. For most radiomics features, the imaging variability was small relative to the inter-patient feature variability in non–small cell lung cancer and head and neck squamous cell carcinoma patient cohorts. From this study, we conclude that using controlled scans can reduce the variability in radiomics features, and our results demonstrate the importance of using controlled protocols in prospective radiomics studies.